Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Evofem Biosciences, Inc. EVFM

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$20.2M
▲ 4.2% YoY
$391,000
$-2.0M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

Our first commercial product, PHEXX®, was approved by the FDA on May 22, 2020, for the prevention of pregnancy and launched in the U.S. in September 2020. We acquired global rights to SOLOSEC® on July 14, 2024 and relaunched the brand in November 2024. Evofem’s commercial operations are focused on the U.S., which is the largest commercial market worldwide and which we believe presents the greatest opportunity for PHEXX, SOLOSEC, and other women’s health products. As of February 28, 2026, we had a total of 29 full-time employees.

Written from the business description in Evofem Biosciences, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 11 March 2026. Every sentence was checked against that document before publication.

Growth

USD 20.2M
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 20.2 · Net income 0.4
20M40M-100M-200M
20132016201920222025
Compound annual growth
+6.2%
+114.4%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +114.4% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

2 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating 16.7% · Net 1.9%
-10000%-20000%
201320192025
ROE
FY2020 · ROE -1675.9%
-500%-1000%-1500%
201320192025
Three returns, three denominators.
Return on equityNot applicable: equity was zero or negative in this period, so return on equity has no meaning.
Return on capital employedNot applicable: capital employed was zero or negative in this period, so return on capital employed has no meaning.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -2.0
-100M-200M
201320192025
Net buybacks $ Dividends $
FY2022 · Dividends · · Net buybacks 18000.0
100000200000
201820212022

Total assetsUSD 20.3M
EquityUSD -74.3M
CashUSD 578,000.00
Gross debtUSD 147,000.00
Net debtUSD -431,000.00
Current ratio0.18×

Equity was zero or negative — liabilities equaled or exceeded assets. No ratio is shown.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
EVFM, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.00.00.00.00.00.00.0◌◌◌◌◌◌
Operating income $B0.0−0.0−0.0−0.1−0.2−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0
EBITDA $B0.0−0.0−0.0◌◌◌◌◌◌◌◌◌◌
Income tax $B0.0◌0.00.00.00.00.00.00.00.00.00.0◌
Net income $B0.0−0.00.1−0.1−0.2−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.1−0.1−0.1−0.1−0.1−0.0◌−0.0−0.0−0.0
EPS, diluted $0.00−0.110.05−167.42−23.63−2.12−1.99−5.74−55.78−5.66−18.91−5.36−29.33
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout %———————−0—————
ROE %—————−1675.9————−96.9——
Shares out B0.130.110.020.000.160.080.050.030.000.010.010.01◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 49 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. 12 checks were skipped: revenue is not tagged before 2019. Six checks were skipped: EPS is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image